CD8A and neoplasm: Several targets including RNF43fs, TGFBR2fs, ASTE1fs, AIM2fs, have been extensively validated in numerous immunological assays: priming and boosting naïve T cell populations in healthy donors, confirming cytotoxic capacity of CD8+ T cell responses in tumor killing assays and detecting frameshift-specific memory responses within blood and tumor T cell compartments in dMMR cancer patients and Lynch syndrome populations (71, 83–85).